PRA expands European ops with new Dutch and British offices

As it continues to grow into a competitive CRO, PRA will need to expand its operations in Europe with the opening of new offices in the U.K. and the Netherlands, the company announced Monday.

Opening a facility in the Dutch city of Utrecht--PRA's fourth in the country--will give more than 20 PRA employees a home base in the region to support the CRO's product registration trials. Previously they could only do that in PRA's office in Mechelen, Belgium. In Reading, England, more than 240 PRA employees will relocate to a larger office in the city to accommodate growth.

More importantly, the new offices will house PRA's increasing staff and demand for its Phase IIa-IIIb service offerings, according to a statement from the CRO. The decision comes on the heels of PRA securing an exclusive deal to conduct worldwide Phase III biosimilar studies for big biotech Amgen ($AMGN) and a drug development partnership with USB, according to PMLiVE.

PRA has opened 9 offices in Europe since 2009, according the company.

- see the story from PMLiVE
- here's the PRA release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.